A novel effort from Microsoft and Adaptive Biotechnologies to diagnose multiple diseases from a single blood test is a data challenge on the scale of Google search. “Google categorized the… Read More
Kristin Anderson has already fought cancer in more ways than one. She’s a cancer survivor whose battle with breast cancer started when she was just 28 years old and pursuing… Read More
As a journalist, Luke Timmerman has covered biotech for more than 17 years. Now, the Timmerman Report founder is making headlines for his efforts to raise money for cancer research.… Read More
Seattle biotech journalist Luke Timmerman reached new heights Tuesday in his efforts to raise awareness for cancer research by successfully summiting Mount Everest. A series of tweets and photographs showed… Read More
Luke Timmerman started climbing mountains with college buddies when he was in his 20s. He’s climbed Mount Rainier in Washington state (14,400 feet), Alaska’s Denali (20,000 feet) and even Argentina’s… Read More
Four decades ago, the overall chance of someone surviving cancer was about 50-50— not exactly a promising outlook. Today, those numbers have dramatically increased as new drugs and cancer-fighting biotechnologies… Read More
Biotech journalist Luke Timmerman spends most of his time reading and writing about medical innovation. But now, he’s doing a lot more: Literally climbing Mount Everest to raise awareness, and… Read More
In the quest for a better understanding of the human body, the automated DNA sequencer was a breakthrough innovation, giving scientists new insights into the hidden code of life. The… Read More
“Mr. Gates, I Quit.” That’s the opening chapter of “Hood: Trailblazer of the Genomics Age,” and it’s just the first indication that this is no run-of-the-mill biography. In documenting the life and… Read More
Luke Timmerman, a respected biotechnology journalist known for his past work at The Seattle Times and Xconomy, today launched a new subscription-based biotech news site, The Timmerman Report. The debut comes as Timmerman puts the… Read More
Amgen dealt a blow to Seattle’s biotech industry last week with the announcement that it will be closing its large research-and-development campus on Elliott Bay, which dates back to its acquisition of… Read More
—Mason Morfit, president of ValueAct Capital, has joined Microsoft’s board and will also serve on the board’s audit committee. Morfit’s appointment is part of a prior agreement between the software giant and the San Francisco-based… Read More